SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

Investors are actively debating UAMY's role in Western technological sovereignty as the stock benefits from a broader rotation into critical minerals and rare earth plays tied to AI infrastructure and national defense. The community remains hyper-focused on supply chain scarcity and potential institutional accumulation while navigating the persistent volatility and intense short-selling activity typical of this sector.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors aggressively position themselves ahead of the upcoming earnings report, with the community intensely debating whether the company's hardware dominance can fuel an AI-driven breakout. Traders are focused on potential guidance regarding future AI integration and hardware demand, balancing optimism over strong Chinese market sales against concerns about high implied volatility and a history of post-earnings price weakness.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing increased investor activity and community interest following the start of R2 production and the company's efforts to maintain operational timelines despite recent weather challenges. Discussions are heavily focused on the stock's potential for an earnings-driven breakout, with participants closely debating the company's path to profitability and the impact of the upcoming R2 vehicle launch.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc. is trending as investors brace for upcoming earnings, with community sentiment split between those anticipating a major beat driven by AI monetization and skeptics warning of volatility due to its correlation with broader software and meme stock trends. Market participants are intensely focused on user growth metrics and how ad revenue performance will be interpreted against competitive benchmarks.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is rallying following the FDA's acceptance of its sNDA for AXS-05 to treat Alzheimer's disease agitation, with a priority review deadline set for April 30. Investors are closely tracking this potential blockbuster catalyst, fueled by strong commercial growth in existing products and multiple analyst upgrades suggesting significant upside potential.

Huachen AI Parking Management Technology Holding Co., Ltd. engages in the provision of smart parking solutions and equipment structural parts. Its products include structural parts, garage structural parts, materials such as customized steel and load bearing steel plates for cubic parking equipment, and railroad accessories. The company was founded by Lu Bin on September 30, 2021 and is headquartered in Jiaxing, China.

Huachen AI Parking Management Technology Holding Co. Ltd. - Ordinary Shares - Class A

Huachen AI Parking Management Technology Holding Ord Shs

HCAI is seeing intense volatility driven by its micro-float status following a significant reverse stock split, sparking heavy speculation and a flurry of high-stakes trading. The community remains sharply divided, with bulls betting on explosive squeeze potential and short-term momentum, while skeptics warn of classic pump-and-dump characteristics common in low-float ADRs.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors closely monitor its heavy AI capital expenditures, with the community actively debating whether the company's aggressive infrastructure investments in Gemini and Cloud integration will sustain its recent growth or lead to margin pressure. Sentiment is polarized between bulls highlighting Google's dominant AI stack as a long-term compounder and skeptics wary of the broader sector's reliance on circular capital investment cycles.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors digest a blowout quarterly report that featured record AWS revenue growth and a rapidly expanding custom silicon business. While the market is navigating broader sector volatility linked to surging AI capital expenditure across the hyperscaler landscape, community members are actively debating the sustainability of these massive infrastructure investments versus the company's long-term growth and profitability.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to the company's progress on Phase 3 trials and growing anticipation for upcoming maintenance data, which community members view as a pivotal catalyst for demonstrating long-term drug durability. Investors are actively debating the potential for a partnership or buyout, weighing the company's standalone development strategy against the competitive landscape of the obesity market.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta shares are facing selling pressure after the company raised its full-year capital expenditure guidance to support ongoing AI infrastructure expansion, sparking concerns about the timeline for return on investment. While the broader market remains resilient, investors are actively debating whether this massive spending surge signals long-term AI leadership or an overextension of the company's balance sheet.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $69,650.76 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 95,412 shares of the company's stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $0.73, for a total value of $69,650.76. Following the completion of the sale...

<ul class="summary-bullets"><li>The workforce reduction will be “substantially completed” by Feb. 13.&nbsp;</li><li>As part of the workforce reduction efforts, the company expects to incur a one-time charge of $4.1 million in the first quarter.</li><li>CFO Timothy W. Trost and chief medical officer (CMO) Randi Isaacs will resign as part of the move.</li></ul>Werewolf Therapeutics, Inc. (HOWL) has decided to reduce its workforce by 64% as it seeks to lower its operating costs, the company said in a filing with the Securities and Exchange Commission on Friday.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001785530/000119312526051455/d110809d8k.htm">said</a> that the decision was approved by its Board of Directors on Feb. 9, and the workforce reduction will be “substantially completed” by Feb. 13.As part of the workforce reduction efforts, the company expects to incur a one-time charge of $4.1 million in the first quarter. The amount includes employee separation benefits, including severance and related benefits.Shares of the company rose over 4% after hours after closing down 1% in the regular trading session.<h2 class="st-heading-2">CFO &amp; CMO Exits</h2>CFO Timothy W. Trost and chief medical officer (CMO) Randi Isaacs will resign as part of the move and are entitled to severance benefits including an amount equal to nine months of their base salary, Werewolf Therapeutics said. &nbsp;However, both the executives will assist in aiding a transition of their responsibilities from time to time for up to six months. &nbsp;The company also said on Friday that it is evaluating alternatives such as strategic partnerships for further development of its WTX-124 and WTX-330 INDUKINE programs. It sought to raise capital in the fourth quarter of 2025 as well as the first quarter of 2026 to fund operations and has engaged in investor discussions regarding pipeline and financing, it added.However, the company said on Friday that there is no guarantee that any transaction would occur.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around HOWL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<a href="https://stocktwits.com/symbol/HOWL">HOWL stock</a> has dropped 57% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/disc-medicine-stock-slumps-after-fda-declines-approval-for-inherited-disorder-drug/cZRd2YMR4tK">Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Werewolf Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives

The company said that the decision to layoff 64% of its workforce was approved by its board of directions on Feb. 9. 

Equity

The company said that the decision to layoff 64% of its workforce was approved by its board of directions on Feb. 9. 


Luke Evnin Sells 38,782 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 38,782 shares of the company's stock in a transaction on Friday, January 16th. The shares were sold at an average...

Luke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 30,616 shares of the company's stock in a transaction dated Wednesday, January 14th. The stock was sold at an...

Luke Evnin Sells 58,980 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 58,980 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,761.92 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,378 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 18,568 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $22,448.16 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 35,632 shares of the company's stock in a transaction dated Friday, December 26th. The stock was sold at an...

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock in a transaction on Wednesday, December 10th. The stock was sold at...

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Current Price	$0.7381
Prev Close	$0.68
Open	$0.7173
Dividend Yield	0.00%
50-Day Moving Average	$0.8008
Beta	1.72
Avg. Volume	376,340.37
PE Ratio	-0.51

52-Week High	$2.38
52-Week Low	$0.5301
Market Capitalization	$33.05M
EPS (Annual)	-$1.33
Price to Book	1.33
Revenue Per Employee	$0.00

HOWL
Werewolf Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HOWL News

HOWLWerewolf Therapeutics Inc